1. Upadacitinib approved for giant cell arteritis based on phase III trial data.
2. Higher remission rates compared to placebo were observed.
3. Safety considerations include serious infections and cardiovascular events.
4. Multiple indications across rheumatology, gastroenterology, and dermatology.
5. GCA predominantly affects Caucasian women over 50 years, with a peak incidence between 70 and 80 years.

Source: AbbVie